Ghent University Academic Bibliography

Show Sort by

Your filters: cql: author="Yaniv, Isaac" or (type exact bookEditor and editor="Yaniv, Isaac")

Add to list
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN) : a multicentre, randomised, phase 3 trial

Ruth Ladenstein, Ulrike Poetschger, Dominique Valteau-Couanet, Roberto Luksch, Victoria Castel, Isaac Yaniv, Genevieve Laureys (UGent) , Penelope Brock, Jean Marie Michon, Cormac Owens, et al.

(2018) LANCET ONCOLOGY. 19(12). p.1617-1629
Add to list
Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN) : an international, randomised, multi-arm, open-label, phase 3 trial

Ruth Ladenstein, Ulrike Pötschger, Andrew D. J. Pearson, Penelope Brock, Roberto Luksch, Victoria Castel, Isaac Yaniv, Vassilios Papadakis, Genevieve Laureys (UGent) , Josef Malis, et al.

(2017) LANCET ONCOLOGY. 18(4). p.500-514
Add to list
Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers

André Oberthuer, Dilafruz Juraeva, Barbara Hero, Ruth Volland, Carolina Sterz, Rene Schmidt, Andreas Faldum, Yvonne Kahlert, Anne Engesser, Shahab Asgharzadeh, et al.

(2015) CLINICAL CANCER RESEARCH. 21(8). p.1904-1915
Add to list
- Conference Paper
- C3
The prognostic value of semi-quantitative 123I MIBG scintigraphy at diagnosis in high risk neuroblastoma: validation of the SIOPEN score method

Ruth Ladenstein, Ulrike Poetschger, Ariane Boubaker, Zvi Bar-Sever, Brent Drake, Anton Staudenherz, Maria Rita Castellani, Bieke Lambert (UGent) , Katheryn Grange, Penelope Brock, et al.

(2011) PEDIATRIC BLOOD & CANCER. 57(5). p.732-733
Add to list
EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells

An De Weer, Joni Van der Meulen (UGent) , Pieter Rondou (UGent) , Tom Taghon (UGent) , Torsten A Konrad, Katleen De Preter (UGent) , Pieter Mestdagh (UGent) , Tom Van Maerken (UGent) , Nadine Van Roy (UGent) , Marta Jeison, et al.

(2011) BRITISH JOURNAL OF HAEMATOLOGY. 154(3). p.337-348
Add to list
Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the european HR-NBL1/SIOPEN study

Ruth Ladenstein, Domonique Valteau-Couanet, Penelope Brock, Isaac Yaniv, Victoria Castel, Genevieve Laureys (UGent) , Josef Malis, Vassilios Papadakis, Ana Lacerda, Ellen Ruud, et al.

(2010) JOURNAL OF CLINICAL ONCOLOGY. 28(21). p.3516-3524
Add to list
Prognostic impact of gene expression-based classification for neuroblastoma

Andre Oberthuer, Barbara Hero, Frank Berthold, Dilafruz Juraeva, Andreas Faldum, Yvonne Kahlert, Shahab Asgharzadeh, Robert Seeger, Paola Scaruffi, Gian Paolo Tonini, et al.

(2010) JOURNAL OF CLINICAL ONCOLOGY. 28(21). p.3506-3515
Add to list
- Conference Paper
- C3
Downregulation of miR-449a is essential for the survival of EVI1 positive leukemic cells through modulation of NOTCH1 and BCL2

An De Weer, Pieter Mestdagh (UGent) , Katleen De Preter (UGent) , Joni Van der Meulen (UGent) , Pieter Van Vlierberghe (UGent) , Tom Van Maerken (UGent) , Nadine Van Roy (UGent) , Marta Jeison, Isaac Yaniv, Barbara Cauwelier, et al.

(2009) BLOOD. 114(22). p.152-153

Academic Bibliography

Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN) : a multicentre, randomised, phase 3 trial

Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN) : an international, randomised, multi-arm, open-label, phase 3 trial

Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers

The prognostic value of semi-quantitative 123I MIBG scintigraphy at diagnosis in high risk neuroblastoma: validation of the SIOPEN score method

EVI1-mediated down regulation of MIR449A is essential for the survival of EVI1 positive leukaemic cells

Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: the european HR-NBL1/SIOPEN study

Prognostic impact of gene expression-based classification for neuroblastoma

Downregulation of miR-449a is essential for the survival of EVI1 positive leukemic cells through modulation of NOTCH1 and BCL2

Contents

Support

Contact